NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Sigyn Therapeutics' CardioDialysis™ for Cardiovascular Disease Treatment
TL;DR
Sigyn Therapeutics' CardioDialysis offers a competitive edge by potentially achieving 75-95% MACE reduction using existing dialysis infrastructure, surpassing current drug limitations.
CardioDialysis works by deploying broad-spectrum blood purification on existing dialysis machines to clear inflammatory molecules and lipoproteins, with clinical trials planned in dialysis clinic settings.
This therapy could significantly extend lives by reducing cardiovascular deaths, particularly benefiting ESRD patients who face 20 times higher cardiovascular disease incidence.
CardioDialysis transforms kidney dialysis clinics into cardiovascular treatment centers, potentially adding $2.8 billion monthly to dialysis industry revenues by extending patient lives.
Found this article helpful?
Share it with your network and spread the knowledge!
CardioDialysis™ is a dialysis-like therapy being developed by Sigyn Therapeutics to treat cardiovascular disease by purifying blood to remove harmful molecules, with the goal of extending lives and reducing Major Adverse Cardiovascular Events (MACE).
It could potentially improve upon the 75-95% MACE reductions reported for blood purification therapies while overcoming infrastructure limitations that constrain current lipoprotein apheresis treatments, which are only available at about 60 specialized centers in the U.S.
CardioDialysis™ is designed to be deployed on existing dialysis machines at over 7,500 kidney dialysis clinics, unlike lipoprotein apheresis devices that require specialized equipment and cannot operate on standard dialysis machines.
In vitro studies have validated CardioDialysis™'s ability to clear twelve therapeutic targets below 200nm in diameter from human blood plasma, including inflammatory molecules not addressed by current market-approved therapies.
Sigyn Therapeutics, led by inventor CEO Jim Joyce, is developing CardioDialysis™, with an early clinical opportunity to treat cardiovascular disease in end-stage renal disease (ESRD) patients during their regular dialysis treatments.
According to the American Heart Association, blood purification (lipoprotein apheresis) is associated with 75-95% reductions in MACE, compared to 25% reductions with LDL-C reducing statins like Lipitor, Crestor, and Zocor.
CardioDialysis™ has been observed to be safe and well tolerated in porcine animal studies conducted at the University of Michigan, though human clinical data is not yet mentioned in the provided content.
Cardiovascular disease accounts for 67% of ESRD patient deaths, and its incidence is up to 20 times higher in ESRD patients compared to the general population, making this a critical unmet medical need.
While statins like Lipitor, Crestor, and Zocor are associated with 25% reductions in MACE, blood purification approaches like CardioDialysis™ aim to achieve 75-95% reductions based on American Heart Association reports about similar therapies.
Curated from NewMediaWire
